Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Yale University
NIH’s National Cancer Institute licensed two experimental cancer therapies in the past month to biopharma firms, leading a heavy slate of cancer-focused tech transfer deal-making.
Private Company Edition: BioGeneration closed a €105m ($119m) fund to continue backing new European companies, while Samsara BioCapital, Evotec and KCK Ltd. launched the virtual incubator Autobahn Labs. Also, Poseida, Annexon and Goldfinch close $100m-plus VC rounds.
The Bayh-Dole act of 1980 facilitated deal-making between private-sector firms and research institutions, largely seeding the US biotech industry. Plus, an overview of the latest tech transfer deals.
As US cases set to reach half a million, FDA gives green light to blood plasma trials to help meet urgent need for therapies.
- Academic and Research Institutions